• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

手术治疗局限性透明细胞肾细胞癌的临床和病理因素的预后价值

Prognostic value of clinical and pathological factors for surgically treated localized clear cell renal cell carcinoma.

作者信息

Teng Jingfei, Gao Yi, Chen Ming, Wang Kai, Cui Xingang, Liu Yushan, Xu Danfeng

机构信息

Department of Urology, General Hospital of Beijing Military Command, Beijing 100700, China.

Department of Urology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.

出版信息

Chin Med J (Engl). 2014;127(9):1640-4.

PMID:24791867
Abstract

BACKGROUND

Surgical resection is the most effective treatment for renal cell carcinoma (RCC). Currently several prognostic factors and models are used for outcome prediction. However, whether intratumoral changes are independent prognostic factors for RCC or not remains unclear. The aim of the study was to investigate the prognostic roles of intratumoral changes in surgical treated localized clear cell renal cell carcinoma (ccRCC).

METHODS

Patients who received partial or radical nephrectomy between 2004 and 2009 in our center were retrospectively reviewed. Univariate and multivariate analyses were used to assess gender, age, body mass index (BMI), intratumoral hemorrhage, tumor necrosis, cystic degeneration, sarcomatoid change, Ki-67 expression, Fuhrman grade, and T stage on recurrence-free survival (RFS) and cancer-specific survival (CSS).

RESULTS

A total of 378 patients were included in our study. In univariate analysis, age, BMI, intratumoral hemorrhage, tumor necrosis, sarcomatoid change, Ki-67 expression level, Fuhrman grade, and T stage were prognostic factors for RFS. Age, BMI, tumor necrosis, sarcomatoid change, Ki-67 expression level, Fuhrman grade, and T stage were prognostic factors effecting CSS. In multivariate analysis, age, BMI, tumor necrosis, sarcomatoid change, Ki-67, Fuhrman grade, and T stage were independent prognostic factors for both RFS and CSS.

CONCLUSION

Intratumoral changes such as tumor necrosis and sarcomatoid change are independent prognostic factors for ccRCC.

摘要

背景

手术切除是肾细胞癌(RCC)最有效的治疗方法。目前有多种预后因素和模型用于预测预后。然而,肿瘤内变化是否为RCC的独立预后因素仍不清楚。本研究的目的是探讨肿瘤内变化在手术治疗局限性透明细胞肾细胞癌(ccRCC)中的预后作用。

方法

回顾性分析2004年至2009年在本中心接受部分或根治性肾切除术的患者。采用单因素和多因素分析评估性别、年龄、体重指数(BMI)、肿瘤内出血、肿瘤坏死、囊性变、肉瘤样变、Ki-67表达、Fuhrman分级和T分期对无复发生存期(RFS)和癌症特异性生存期(CSS)的影响。

结果

本研究共纳入378例患者。单因素分析中,年龄、BMI、肿瘤内出血、肿瘤坏死、肉瘤样变、Ki-67表达水平、Fuhrman分级和T分期是RFS的预后因素。年龄、BMI、肿瘤坏死、肉瘤样变、Ki-67表达水平、Fuhrman分级和T分期是影响CSS的预后因素。多因素分析中,年龄、BMI、肿瘤坏死、肉瘤样变、Ki-67、Fuhrman分级和T分期是RFS和CSS的独立预后因素。

结论

肿瘤坏死和肉瘤样变等肿瘤内变化是ccRCC的独立预后因素。

相似文献

1
Prognostic value of clinical and pathological factors for surgically treated localized clear cell renal cell carcinoma.手术治疗局限性透明细胞肾细胞癌的临床和病理因素的预后价值
Chin Med J (Engl). 2014;127(9):1640-4.
2
Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.嫌色细胞肾细胞癌(RCC):大型多中心系列中的肿瘤学结果和预后因素。
BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.
3
pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.pT1期透明细胞肾细胞癌:MIB-1增殖活性与病理特征及癌症特异性生存之间的关联研究
Cancer. 2002 Apr 15;94(8):2180-4. doi: 10.1002/cncr.10433.
4
[Pathological prognostic indicators in renal cell carcinoma].[肾细胞癌的病理预后指标]
Actas Urol Esp. 2010 Jan;34(1):71-7.
5
Prognostic factor for Korean patients with renal cell carcinoma and venous tumor thrombus extension: application of the new 2009 TNM staging system.韩国肾细胞癌伴静脉瘤栓患者的预后因素:新 2009 年 TNM 分期系统的应用。
Int Braz J Urol. 2013 May-Jun;39(3):353-63. doi: 10.1590/S1677-5538.IBJU.2013.03.08.
6
Prognostic significance of p21-activated kinase 6 expression in patients with clear cell renal cell carcinoma.p21激活激酶6表达在透明细胞肾细胞癌患者中的预后意义
Ann Surg Oncol. 2014 Dec;21 Suppl 4:S575-83. doi: 10.1245/s10434-014-3680-z. Epub 2014 Apr 9.
7
Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers.组织学坏死对非转移性透明细胞肾细胞癌的预后作用:与病理特征及分子标志物的相关性
J Urol. 2008 Oct;180(4):1284-9. doi: 10.1016/j.juro.2008.06.036. Epub 2008 Aug 15.
8
Verification of the International Society of Urological Pathology recommendations in Japanese patients with clear cell renal cell carcinoma.验证国际泌尿病理学会建议在日本透明细胞肾细胞癌患者中的应用。
Int J Oncol. 2018 Apr;52(4):1139-1148. doi: 10.3892/ijo.2018.4294. Epub 2018 Feb 28.
9
The post-operative pathological prognostic parameters of clear cell renal cell carcinoma in pT1a cases.pT1a 期透明细胞肾细胞癌的术后病理预后参数。
Pathol Int. 2011 Mar;61(3):116-21. doi: 10.1111/j.1440-1827.2010.02633.x. Epub 2011 Jan 9.
10
Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other.Ki-67和凝固性肿瘤坏死是透明细胞肾细胞癌患者预后不良的独立预测因素,且彼此并非替代指标。
Cancer. 2007 Aug 15;110(4):783-90. doi: 10.1002/cncr.22840.

引用本文的文献

1
MiR-24-1-5p Hinders Malignant Phenotypes of Clear Cell Renal Cell Carcinoma by Targeting SHOX2.miR-24-1-5p 通过靶向 SHOX2 抑制肾透明细胞癌的恶性表型。
Biochem Genet. 2023 Oct;61(5):2004-2019. doi: 10.1007/s10528-023-10353-5. Epub 2023 Mar 14.
2
A novel prognostic model based on six methylation-driven genes predicts overall survival for patients with clear cell renal cell carcinoma.一种基于六个甲基化驱动基因的新型预后模型可预测透明细胞肾细胞癌患者的总生存期。
Front Genet. 2022 Oct 18;13:996291. doi: 10.3389/fgene.2022.996291. eCollection 2022.
3
Key genes associated with prognosis and metastasis of clear cell renal cell carcinoma.
与透明细胞肾细胞癌预后和转移相关的关键基因。
PeerJ. 2022 Jan 4;10:e12493. doi: 10.7717/peerj.12493. eCollection 2022.
4
Comparison of Different Machine Models Based on Contrast-Enhanced Computed Tomography Radiomic Features to Differentiate High From Low Grade Clear Cell Renal Cell Carcinomas.基于对比增强计算机断层扫描影像组学特征比较不同机器模型以鉴别高分级与低分级透明细胞肾细胞癌
Front Oncol. 2021 May 26;11:659969. doi: 10.3389/fonc.2021.659969. eCollection 2021.
5
Ubiquitin-specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NF-κB pathway inactivation.泛素特异性肽酶 53 通过抑制 NF-κB 通路失活抑制肾透明细胞癌的发生发展。
Cancer Med. 2021 Jun;10(11):3674-3688. doi: 10.1002/cam4.3911. Epub 2021 May 11.
6
Leptin Is Associated with Poor Clinical Outcomes and Promotes Clear Cell Renal Cell Carcinoma Progression.瘦素与不良临床结局相关,并促进透明细胞肾细胞癌的进展。
Biomolecules. 2021 Mar 15;11(3):431. doi: 10.3390/biom11030431.
7
High MCM6 Expression as a Potential Prognostic Marker in Clear-cell Renal Cell Carcinoma.高 MCM6 表达可作为透明细胞肾细胞癌的一种潜在预后标志物。
In Vivo. 2021 Jan-Feb;35(1):299-306. doi: 10.21873/invivo.12259.
8
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.透明细胞肾细胞癌患者的增殖潜能及对纳武单抗的反应
Oncoimmunology. 2020 Jun 10;9(1):1773200. doi: 10.1080/2162402X.2020.1773200.
9
Prognostic Value of DNA Methylation-Driven Genes in Clear Cell Renal Cell Carcinoma: A Study Based on Methylation and Transcriptome Analyses.基于甲基化和转录组分析的 DNA 甲基化驱动基因在透明细胞肾细胞癌中的预后价值研究。
Dis Markers. 2020 Jul 11;2020:8817652. doi: 10.1155/2020/8817652. eCollection 2020.
10
Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma.术后临床无转移肾细胞癌的预后分析。
Cancer Med. 2020 Feb;9(3):959-970. doi: 10.1002/cam4.2775. Epub 2019 Dec 16.